Identification of Small Molecule Inhibitors of Clostridium Perfringens ε-toxin cytotoxicity using a Cell-Based High-Throughput Screen

Toxins

Volumn 2, Issue 7, 2010, Pages 1825-1847

  Lewis, Michelle ^a   Weaver, Charles David ^a,b   McClain, Mark S ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Bacterial toxins; Cell membrane permeability; Clostridium perfringens; Drug evaluation; Preclinical; Small molecule libraries; Structure activity relationship

Indexed keywords

4 [3 (AZEPAN 1 YL) 6 OXO 6H ANTHRA[1,9 CD]ISOXAZOL 5 YLAMINO]BUTANOIC ACID; 4 TERT BUTYL N CYCLOOCTYLBENZAMIDE; ANTISERUM; CLOSTRIDIUM EPSILON TOXIN; CLOSTRIDIUM TOXIN; N CYCLOHEXYL 7 METHOXY N METHYLFURO[2,3 B]QUINOLINE 2 CARBOXAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CELL PERMEABILIZATION; CELL SURVIVAL; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; CYTOTOXICITY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM PERFRINGENS;

EID: 79952078425     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins2071825     Document Type: Article

References (49)

1. Gill, D.M. Bacterial toxins: A table of lethal amounts. Microbiol. Rev. 1982, 46, 86-94.
2. Minami, J.; Katayama, S.; Matsushita, O.; Matsushita, C.; Okabe, A. Lambda-toxin of Clostridium perfringens activates the precursor of epsilon-toxin by releasing its N- and C-terminal peptides. Microbiol. Immunol. 1997, 41, 527-535.
3. Gleeson-White, M.H.; Bullen, J.J. Clostridium welchii epsilon toxin in the intestinal contents of man. Lancet 1955, 268, 384-385.
4. Kohn, J.; Warrack, G.H. Recovery of clostridium welchii type d from man. Lancet 1955, 268, 385.
5. Smith, L.D.S.; Williams, B.L. The Pathogenic Anaerobic Bacteria, 3rd ed.; Charles C. Thomas: Springfield, IL, USA, 1984.
6. Miller, C.; Florman, S.; Kim-Schluger, L.; Lento, P.; De La Garza, J.; Wu, J.; Xie, B.; Zhang, W.; Bottone, E.; Zhang, D.; Schwartz, M. Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl. 2004, 10, 1315-1319.
7. Morinaga, G.; Nakamura, T.; Yoshizawa, J.; Nishida, S. Isolation of Clostridium perfringens type D from a case of gas gangrene. J. Bacteriol. 1965, 90, 826.
8. Soler-Jover, A.; Blasi, J.; de Aranda, I.G.; Navarro, P.; Gibert, M.; Popoff, M.R.; Martin-Satue, M. Effect of epsilon toxin-GFP on MDCK cells and renal tubules in vivo. J. Histochem. Cytochem. 2004, 52, 931-942.
9. Soler-Jover, A.; Dorca, J.; Popoff, M.R.; Gibert, M.; Saura, J.; Tusell, J.M.; Serratosa, J.; Blasi, J.; Martin-Satue, M. Distribution of Clostridium perfringens epsilon toxin in the brains of acutely intoxicated mice and its effect upon glial cells. Toxicon 2007, 50, 530-540.
10. Tamai, E.; Ishida, T.; Miyata, S.; Matsushita, O.; Suda, H.; Kobayashi, S.; Sonobe, H.; Okabe, A. Accumulation of Clostridium perfringens epsilon-toxin in the mouse kidney and its possible biological significance. Infect. Immun. 2003, 71, 5371-5375.
11. Miyata, S.; Matsushita, O.; Minami, J.; Katayama, S.; Shimamoto, S.; Okabe, A. Cleavage of a C-terminal peptide is essential for heptamerization of Clostridium perfringens epsilon-toxin in the synaptosomal membrane. J. Biol. Chem. 2001, 276, 13778-13783.
12. Miyata, S.; Minami, J.; Tamai, E.; Matsushita, O.; Shimamoto, S.; Okabe, A. Clostridium perfringens epsilon-toxin forms a heptameric pore within the detergent-insoluble microdomains of madin-darby canine kidney cells and rat synaptosomes. J. Biol. Chem. 2002, 277, 39463-39468.
13. Petit, L.; Gibert, M.; Gillet, D.; Laurent-Winter, C.; Boquet, P.; Popoff, M.R. Clostridium perfringens epsilon-toxin acts on MDCK cells by forming a large membrane complex. J. Bacteriol. 1997, 179, 6480-6487.
14. Petit, L.; Maier, E.; Gibert, M.; Popoff, M.R.; Benz, R. Clostridium perfringens epsilon toxin induces a rapid change of cell membrane permeability to ions and forms channels in artificial lipid bilayers. J. Biol. Chem. 2001, 276, 15736-15740.
15. Petit, L.; Gibert, M.; Gourch, A.; Bens, M.; Vandewalle, A.; Popoff, M.R. Clostridium perfringens epsilon toxin rapidly decreases membrane barrier permeability of polarized MDCK cells. Cell. Microbiol. 2003, 5, 155-164.
16. McClain, M.S.; Cover, T.L. Functional analysis of neutralizing antibodies against Clostridium perfringens epsilon-toxin. Infect. Immun. 2007, 75, 1785-1793.
17. Nagahama, M.; Ochi, S.; Sakurai, J. Assembly of Clostridium perfringens epsilon-toxin on MDCK cell membrane. J. Nat. Toxins 1998, 7, 291-302.
18. Lindsay, C.D. Assessment of aspects of the toxicity of Clostridium perfringens epsilon-toxin using the MDCK cell line. Hum. Exp. Toxicol. 1996, 15, 904-908.
19. Odendaal, M.W.; Visser, J.J.; Botha, W.J.; Prinsloo, H. The passive protection of lambs against Clostridium perfringens type D with semi-purified hyperimmune serum. Onderstepoort J. Vet. Res. 1988, 55, 47-50.
20. Uzal, F.A.; Bodero, D.A.; Kelly, W.R.; Nielsen, K. Variability of serum antibody responses of goat kids to a commercial Clostridium perfringens epsilon toxoid vaccine. Vet. Rec. 1998, 143, 472-474.
21. Aiello, S.E. Merck Veterinary Manual, 8th ed.; Merck and Co., Inc.: Whitehouse Station, NJ, USA, 2003.
22. Pelish, T.M.; McClain, M.S. Dominant-negative inhibitors of the Clostridium perfringens epsilontoxin. J. Biol. Chem. 2009, 284, 29446-29453.
23. Hauer, P.J.; Clough, N.E. Development of monoclonal antibodies suitable for use in antigen quantification potency tests for clostridial veterinary vaccines. Dev. Biol. Stand. 1999, 101, 85-94.
24. Zhang, J.H.; Chung, T.D.; Oldenburg, K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 1999, 4, 67-73.
25. Payne, D.W.; Williamson, E.D.; Havard, H.; Modi, N.; Brown, J. Evaluation of a new cytotoxicity assay for Clostridium perfringens type D epsilon toxin. FEMS Microbiol. Lett. 1994, 116, 161-167.
26. Makarenkov, V.; Kevorkov, D.; Zentilli, P.; Gagarin, A.; Malo, N.; Nadon, R. Hts-corrector: Software for the statistical analysis and correction of experimental high-throughput screening data. Bioinformatics 2006, 22, 1408-1409.
27. Tukey, J.W. A survey of sampling from contaminated distributions. In Contributions to Probability and Statistics; Olkin, I., Ed.; Stanford University Press: Stanford, CA, USA, 1960; pp. 448-485.
28. Malo, N.; Hanley, J.A.; Cerquozzi, S.; Pelletier, J.; Nadon, R. Statistical practice in highthroughput screening data analysis. Nat. Biotechnol. 2006, 24, 167-175.
29. Brideau, C.; Gunter, B.; Pikounis, B.; Liaw, A. Improved statistical methods for hit selection in high-throughput screening. J. Biomol. Screen. 2003, 8, 634-647.
30. Katz, D.; Ito, E.; Lau, K.S.; Mocanu, J.D.; Bastianutto, C.; Schimmer, A.D.; Liu, F.F. Increased efficiency for performing colony formation assays in 96-well plates: Novel applications to combination therapies and high-throughput screening. Biotechniques 2008, 44, ix-xiv.
31. Weiss, J.; Burhenne, J.; Riedel, K.D.; Haefeli, W.E. Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors. AIDS 2002, 16, 674-676.
32. Weiss, J.; Haefeli, W.E. Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: F2 values. Drug Metab. Dispos. 2006, 34, 203-207.
33. Dorca-Arevalo, J.; Soler-Jover, A.; Gibert, M.; Popoff, M.R.; Martin-Satue, M.; Blasi, J. Binding of varepsilon-toxin from Clostridium perfringens in the nervous system. Vet. Microbiol. 2008, 131, 14-25.
34. Casadevall, A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg. Infect. Dis. 2002, 8, 833-841.
35. Lee, Y.S.; Bergson, P.; He, W.S.; Mrksich, M.; Tang, W.J. Discovery of a small molecule that inhibits the interaction of anthrax edema factor with its cellular activator, calmodulin. Chem. Biol. 2004, 11, 1139-1146.
36. Soelaiman, S.; Wei, B.Q.; Bergson, P.; Lee, Y.S.; Shen, Y.; Mrksich, M.; Shoichet, B.K.; Tang, W.J. Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J. Biol. Chem. 2003, 278, 25990-25997.
37. Panchal, R.G.; Hermone, A.R.; Nguyen, T.L.; Wong, T.Y.; Schwarzenbacher, R.; Schmidt, J.; Lane, D.; McGrath, C.; Turk, B.E.; Burnett, J.; Aman, M.J.; Little, S.; Sausville, E.A.; Zaharevitz, D.W.; Cantley, L.C.; Liddington, R.C.; Gussio, R.; Bavari, S. Identification of small molecule inhibitors of anthrax lethal factor. Nat. Struct. Mol. Biol. 2004, 11, 67-72.
38. Burnett, J.C.; Schmidt, J.J.; Stafford, R.G.; Panchal, R.G.; Nguyen, T.L.; Hermone, A.R.; Vennerstrom, J.L.; McGrath, C.F.; Lane, D.J.; Sausville, E.A. Novel small molecule inhibitors of botulinum neurotoxin a metalloprotease activity. Biochem. Biophys. Res. Commun. 2003, 310, 84-93.
39. Zhu, P.J.; Hobson, J.P.; Southall, N.; Qiu, C.; Thomas, C.J.; Lu, J.; Inglese, J.; Zheng, W.; Leppla, S.H.; Bugge, T.H.; Austin, C.P.; Liu, S. Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death. Bioorg. Med. Chem. 2009, 17, 5139-5145.
40. Saenz, J.B.; Doggett, T.A.; Haslam, D.B. Identification and characterization of small molecules that inhibit intracellular toxin transport. Infect. Immun. 2007, 75, 4552-4561.
41. Wahome, P.G.; Bai, Y.; Neal, L.M.; Robertus, J.D.; Mantis, N.J. Identification of small-molecule inhibitors of ricin and shiga toxin using a cell-based high-throughput screen. Toxicon 2010, doi:10.1016/j.toxicon.2010.03.016.
42. Ma, T.; Thiagarajah, J.R.; Yang, H.; Sonawane, N.D.; Folli, C.; Galietta, L.J.; Verkman, A.S. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxininduced intestinal fluid secretion. J. Clin. Invest. 2002, 110, 1651-1658.
43. Peinado, J.R.; Kacprzak, M.M.; Leppla, S.H.; Lindberg, I. Cross-inhibition between furin and lethal factor inhibitors. Biochem. Biophys. Res. Commun. 2004, 321, 601-605.
44. Cole, A.R.; Gibert, M.; Popoff, M.; Moss, D.S.; Titball, R.W.; Basak, A.K. Clostridium perfringens epsilon-toxin shows structural similarity to the pore-forming toxin aerolysin. Nat. Struct. Mol. Biol. 2004, 11, 797-798.
45. Parker, M.W.; Buckley, J.T.; Postma, J.P.; Tucker, A.D.; Leonard, K.; Pattus, F.; Tsernoglou, D. Structure of the aeromonas toxin proaerolysin in its water-soluble and membrane-channel states. Nature 1994, 367, 292-295.
46. Wheeler, D.L.; Barrett, T.; Benson, D.A.; Bryant, S.H.; Canese, K.; Chetvernin, V.; Church, D.M.; DiCuccio, M.; Edgar, R.; Federhen, S.; Geer, L.Y.; Helmberg, W.; Kapustin, Y.; Kenton, D.L.; Khovayko, O.; Lipman, D.J.; Madden, T.L.; Maglott, D.R.; Ostell, J.; Pruitt, K.D.; Schuler, G.D.; Schriml, L.M.; Sequeira, E.; Sherry, S.T.; Sirotkin, K.; Souvorov, A.; Starchenko, G.; Suzek, T.O.; Tatusov, R.; Tatusova, T.A.; Wagner, L.; Yaschenko, E. Database resources of the national center for biotechnology information. Nucleic Acids Res. 2006, 34, D173-D180.
47. Seiler, K.P.; George, G.A.; Happ, M.P.; Bodycombe, N.E.; Carrinski, H.A.; Norton, S.; Brudz, S.; Sullivan, J.P.; Muhlich, J.; Serrano, M.; Ferraiolo, P.; Tolliday, N.J.; Schreiber, S.L.; Clemons, P.A. Chembank: A small-molecule screening and cheminformatics resource database. Nucleic Acids Res. 2008, 36, D351-D359.
48. Wunberg, T.; Hendrix, M.; Hillisch, A.; Lobell, M.; Meier, H.; Schmeck, C.; Wild, H.; Hinzen, B. Improving the hit-to-lead process: Data-driven assessment of drug-like and lead-like screening hits. Drug Discov. Today 2006, 11, 175-180.
49. Keseru, G.M.; Makara, G.M. Hit discovery and hit-to-lead approaches. Drug Discov. Today 2006, 11, 741-748.